Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 261

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 261
---
 the earlier of:                                       |

| 1. | Receipt of a grant                            
 of 327 Euro from the Horizon 2020 Program, or |

| 2. | Consummation of                               
 the merger with OceanTech (refer to Note 1b). |

| The proceeds from the loan agreements were allocated at                                       
 the issuance date to the warrants and to the short-term loan. The warrants were measured      
 at fair value and the remaining amount allocated to the short-term loan. The fair value of    
 the warrants at the measurement date was $288. The short-term loan is subsequently measured   
 at its amortized cost. The Company recorded amortization of a discount as an interest expense 
 of $115 and $173 for the short-term loan, within financial expense line in the statements     
 of comprehensive loss for the year ended December 31, 2024 and 2023, respectively.            |

| As result of the cancellation of the Merger Agreement with 
 OceanTech those warrants were cancelled.                   |

| In April 2024, the Company received the grant from the                                       
 Horizon 2020 Program in the amount of approximately $350 (approximately 327 Euro) and repaid 
 the outstanding balance of the loan received in August 2023 at the amount of $325.           |

| b. | In January 2024,                                                                              
 the Company received a $150 loan from several lenders, including from two directors of the    
 Company (the “January 2024 Loan”). Pursuant to the agreement reached in October               
 2024 (the “2024 Loan Amendment”) with the January 2024 Loan lenders, the January              
 2024 Loan Agreement have been extended until the earlier of an IPO consummation date or until 
 August 31, 2025 (the “Maturity Date”), and bear interest at 8% per annum until                
 maturity, commencing as of September 1, 2024. In addition, at the Maturity Date, the Company  
 will pay the January 2024 Loan lenders an aggregate risk premium equal to $50. Furthermore,   
 upon the occurrence of an IPO, the January 2024 Loan lenders will be granted warrants to      
 purchase such number of Ordinary Shares equal to two times the January 2024 Loan amount,      
 based on a price per share equal to 75% of the lowest price per share of the Ordinary Shares  
 during the first five trading days as of such IPO consummation. As of December 31, 202